Entered into a License Agreement with RIKEN

2006.9.14

Tokyo, Japan –Sep. 1, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced that it has entered into a license agreement with RIKEN. Under the agreement, an exclusive right to market/sublicense pharmaceutical products based on RIKEN’s immune regulating technology is granted to REGiMMUNE from RIKEN.